Dartmouth Health Continuing Education for Professionals Home, Medicine Grand Rounds - Have We Found the Holy Grail of Blood Thinners?, 8/27/2021 8:00:00 AM - 8/27/2024 9:00:00 AM, Participants in Medicine Grand Rounds will be able to identify the most current treatment guidelines, innovations, and standards of practice, and apply them to improve the care of individual patients, promote health and wellness in the population, and achieve clinical quality and safety goals. These educational activities are grounded in principles of health equity, evidence based medicine, inter-professional teamwork, patient-centered care, and respect for human dignity.
Presenter
Meir Preis, MD, PhD
Head, Institute of Hematology
Lady Davis Carmel Medical Center, Haifa, Israel
Assistant Professor of Medicine, Geisel School of Medicine at Dartmouth
Section of Hematology, Dartmouth-Hitchcock Medical Center
About our Presenter
Dr. Meir Preis completed his medical training Cum Laude at the Technion, Israel Institute of Technology and received his PhD in the field of vascular biology. Dr. Preis completed his residency at DHMC in Internal Medicine and became the first resident to join the physician scientist track. He did his fellowship in Hematology-Oncology at DHMC and his research work in the Lab of Dr. Murray Korc, in the field of microRNA expression in pancreatic cancer. Dr. Preis returned to Israel to practice and remains active as an attending physician at DHMC on the hematology inpatient service.
Learning Outcome(s)
At the conclusion of this presentation, participants will be able to describe the role of factor XI in coagulation and hemostasis, including inherited deficiencies, the development of novel approaches for the prevention and treatment of venous thromboembolism and arterial thrombosis using factor XI inhibitors.
Disclosure
The following activity director(s), planning committee member(s), speaker(s), author(s) or anyone in a position to control the content for this activity have reported the following financial relationship(s)* with ineligible company(ies)**. All of the relevant financial relationships listed for these individuals have been mitigated.
* Richard I. Rothstein, MD ~ has research support from Fractyl and is on the Scientific Advisory Board for Allurion.
* Meir Preis, MD, PhD ~ is a consultant/advisor for Janssen.
Other planning committee member(s), speaker(s), activity director(s), author(s) or anyone in a position to control the content for this activity report NO financial relationship(s)* with any ineligible company(ies)**.
* A “financial relationship" includes employee, researcher (named as the PI), consultant, advisor, speaker, independent contractor (including contracted research), royalties or patent beneficiary, executive role, and/or an ownership interest (not including stocks owned in a managed portfolio).
** An ineligible company is any entity whose primary business is producing, marketing, selling, re-selling, or distributing healthcare products used by or on patients.
Bibliographic Material
See presentation for bibliographic sources to allow for further study.
Presenter
Meir Preis, MD, PhD
Head, Institute of Hematology
Lady Davis Carmel Medical Center, Haifa, Israel
Assistant Professor of Medicine, Geisel School of Medicine at Dartmouth
Section of Hematology, Dartmouth-Hitchcock Medical Center
About our Presenter
Dr. Meir Preis completed his medical training Cum Laude at the Technion, Israel Institute of Technology and received his PhD in the field of vascular biology. Dr. Preis completed his residency at DHMC in Internal Medicine and became the first resident to join the physician scientist track. He did his fellowship in Hematology-Oncology at DHMC and his research work in the Lab of Dr. Murray Korc, in the field of microRNA expression in pancreatic cancer. Dr. Preis returned to Israel to practice and remains active as an attending physician at DHMC on the hematology inpatient service.
Learning Outcome(s)
At the conclusion of this presentation, participants will be able to describe the role of factor XI in coagulation and hemostasis, including inherited deficiencies, the development of novel approaches for the prevention and treatment of venous thromboembolism and arterial thrombosis using factor XI inhibitors.
Disclosure
The following activity director(s), planning committee member(s), speaker(s), author(s) or anyone in a position to control the content for this activity have reported the following financial relationship(s)* with ineligible company(ies)**. All of the relevant financial relationships listed for these individuals have been mitigated.
* Richard I. Rothstein, MD ~ has research support from Fractyl and is on the Scientific Advisory Board for Allurion.
* Meir Preis, MD, PhD ~ is a consultant/advisor for Janssen.
Other planning committee member(s), speaker(s), activity director(s), author(s) or anyone in a position to control the content for this activity report NO financial relationship(s)* with any ineligible company(ies)**.
* A “financial relationship" includes employee, researcher (named as the PI), consultant, advisor, speaker, independent contractor (including contracted research), royalties or patent beneficiary, executive role, and/or an ownership interest (not including stocks owned in a managed portfolio).
** An ineligible company is any entity whose primary business is producing, marketing, selling, re-selling, or distributing healthcare products used by or on patients.
Bibliographic Material
See presentation for bibliographic sources to allow for further study.
